NZ284851A - 1-[3-(piperazin-1-yl)-prop-1-yl] benzimidazole derivatives and their use in the treatment of cns disorders - Google Patents

1-[3-(piperazin-1-yl)-prop-1-yl] benzimidazole derivatives and their use in the treatment of cns disorders

Info

Publication number
NZ284851A
NZ284851A NZ284851A NZ28485195A NZ284851A NZ 284851 A NZ284851 A NZ 284851A NZ 284851 A NZ284851 A NZ 284851A NZ 28485195 A NZ28485195 A NZ 28485195A NZ 284851 A NZ284851 A NZ 284851A
Authority
NZ
New Zealand
Prior art keywords
disorders
piperazin
fluoro
phenyl
propan
Prior art date
Application number
NZ284851A
Other languages
English (en)
Inventor
William S Faraci
Anton F J Fliri
Brian T O'neill
Mark A Sanner
Stevin H Zorn
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ284851A publication Critical patent/NZ284851A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
NZ284851A 1994-08-05 1995-05-18 1-[3-(piperazin-1-yl)-prop-1-yl] benzimidazole derivatives and their use in the treatment of cns disorders NZ284851A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28657694A 1994-08-05 1994-08-05
US29800594A 1994-08-30 1994-08-30
PCT/IB1995/000378 WO1996004250A1 (en) 1994-08-05 1995-05-18 Benzimidazole derivatives having dopaminergic activity

Publications (1)

Publication Number Publication Date
NZ284851A true NZ284851A (en) 1998-07-28

Family

ID=26963924

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ284851A NZ284851A (en) 1994-08-05 1995-05-18 1-[3-(piperazin-1-yl)-prop-1-yl] benzimidazole derivatives and their use in the treatment of cns disorders

Country Status (20)

Country Link
EP (1) EP0775118B1 (cg-RX-API-DMAC7.html)
JP (1) JP3004727B2 (cg-RX-API-DMAC7.html)
KR (1) KR970704698A (cg-RX-API-DMAC7.html)
AT (1) ATE242220T1 (cg-RX-API-DMAC7.html)
AU (1) AU703431B2 (cg-RX-API-DMAC7.html)
BR (1) BR9503572A (cg-RX-API-DMAC7.html)
CA (1) CA2196769C (cg-RX-API-DMAC7.html)
CO (1) CO4410330A1 (cg-RX-API-DMAC7.html)
DE (1) DE69530988T2 (cg-RX-API-DMAC7.html)
DK (1) DK0775118T3 (cg-RX-API-DMAC7.html)
ES (1) ES2201105T3 (cg-RX-API-DMAC7.html)
FI (1) FI970469L (cg-RX-API-DMAC7.html)
IL (1) IL114754A0 (cg-RX-API-DMAC7.html)
MX (1) MX9700959A (cg-RX-API-DMAC7.html)
NZ (1) NZ284851A (cg-RX-API-DMAC7.html)
PE (1) PE35796A1 (cg-RX-API-DMAC7.html)
PT (1) PT775118E (cg-RX-API-DMAC7.html)
TR (1) TR199500956A2 (cg-RX-API-DMAC7.html)
TW (1) TW306920B (cg-RX-API-DMAC7.html)
WO (1) WO1996004250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ320537A (en) * 1995-12-21 1999-03-29 Pfizer 2,7-substituted octahydro-pyrrolo(1,2-a)pyrazine derivatives
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
EP1246815B1 (en) * 1999-12-30 2004-03-17 H. Lundbeck A/S Phenylpiperazinyl derivatives
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
CA2429383A1 (en) * 2000-11-22 2002-05-30 Abbott Laboratories Selective dopamine d4 receptor agonists for treating sexual dysfunction
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2002100350A2 (en) * 2001-06-13 2002-12-19 The Regents Of University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
AU2002360335A1 (en) 2001-11-01 2003-05-12 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
KR20040091119A (ko) * 2002-03-12 2004-10-27 와이어쓰 키랄 1,4-이치환된 피페라진의 제조방법
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
EP1719761A4 (en) * 2004-02-23 2007-10-10 Dainippon Sumitomo Pharma Co NEW HETEROCYCLIC CONNECTION
EP1732529A4 (en) 2004-03-25 2009-02-25 Univ Michigan GOSSYPOL KOKRISTALLE AND ITS USE
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
US9802929B2 (en) 2012-11-26 2017-10-31 Shenyang Haiwang Biotechnology Co., Ltd. Benzo five-membered nitrogen heterocyclic piperidine or piperazine derivatives and preparation methods and pharmaceutical compositions thereof
WO2014079155A1 (zh) * 2012-11-26 2014-05-30 辽宁贝雷生物制药有限公司 苯并五元氮杂环基哌嗪或哌啶衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
TR199500956A2 (tr) 1996-07-21
PT775118E (pt) 2003-10-31
FI970469A7 (fi) 1997-04-04
AU2351095A (en) 1996-03-04
WO1996004250A1 (en) 1996-02-15
MX9700959A (es) 1997-05-31
JP3004727B2 (ja) 2000-01-31
PE35796A1 (es) 1996-10-01
DE69530988T2 (de) 2003-12-04
CO4410330A1 (es) 1997-01-09
AU703431B2 (en) 1999-03-25
DE69530988D1 (de) 2003-07-10
ATE242220T1 (de) 2003-06-15
FI970469A0 (fi) 1997-02-04
IL114754A0 (en) 1995-11-27
CA2196769C (en) 2002-10-08
TW306920B (cg-RX-API-DMAC7.html) 1997-06-01
JPH09510706A (ja) 1997-10-28
KR970704698A (ko) 1997-09-06
ES2201105T3 (es) 2004-03-16
EP0775118A1 (en) 1997-05-28
EP0775118B1 (en) 2003-06-04
CA2196769A1 (en) 1996-02-15
BR9503572A (pt) 1996-04-30
FI970469L (fi) 1997-04-04
DK0775118T3 (da) 2003-09-29

Similar Documents

Publication Publication Date Title
US4880810A (en) Quinazolinediones and pyridopyrimidinediones
US4378361A (en) Heterocyclic compounds
US4381309A (en) 1-Aryloxy-2-hydroxy-3-((heterocyclic-substituted alkyl)-amino)-propanes and salts thereof
NZ284851A (en) 1-[3-(piperazin-1-yl)-prop-1-yl] benzimidazole derivatives and their use in the treatment of cns disorders
US7399779B2 (en) 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
EP0765320B1 (en) Benzimidazolone derivatives with central dopaminergic activity
NO309648B1 (no) Indolderivat og farmasöytisk preparat inneholdende dette
US5889010A (en) Benzimidazole derivatives having dopaminergic activity
US5714487A (en) 2,7-substituted octahydro-pyrrolo 1,2-a!pyrazine derivatives
US6114369A (en) Benzimidazole compound
CN1278789A (zh) 作为磷脂酶抑制剂的9,10－二氢－9,10－桥亚乙基蒽衍生物
DE2737630C2 (cg-RX-API-DMAC7.html)
US4797403A (en) Quinazolinediones and pyridopyrimidinediones
RU2147303C1 (ru) Промежуточные продукты и способ получения солей нафтиридонкарбоновой кислоты
US20070135508A1 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
FI114094B (fi) Menetelmä substituoitujen indolonijohdannaisten valmistamiseksi
CN1154693A (zh) 具有多巴胺能活性的苯并咪唑衍生物
WO1995021844A1 (en) 5ht2b receptor antagonists condensed indoles
FR2773800A1 (fr) Derives de benzimidazole, leur procede de preparation et leur application en therapeutique
NZ275689A (en) N-benzyl substituted heterotricyclic derivatives having affinity for the 5-ht1a receptor and medicaments
CZ336499A3 (cs) Benzimidazolové deriváty
JPH08225571A (ja) ６−アルコキシ−１ｈ−ベンゾトリアゾール−５−カルボキサミド誘導体及びその中間体並びに該化合物を含有する医薬組成物
HK1079783B (en) 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists